Cerivastatin (BAY w 6228): A novel HMG-CoA reductase inhibitor

Cardiovascular Drug Reviews

Volumn 16, Issue 3, 1998, Pages 236-263

  Kuhlmann, J ^a   Muck, W ^a   Bischoff, H ^a   Von Keutz, E ^a   Llewellyn, M ^a  

^a BAYER AG   (Germany)

Author keywords

Cerivastatin; Clinical pharmacology; HMG CoA reductase inhibitors; Hypercholesterolemia; Pharmacology; Toxicology

Indexed keywords

ANTACID AGENT; CERIVASTATIN; CHOLESTEROL; CIMETIDINE; CYCLOSPORIN; DIGOXIN; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; NICOTINIC ACID; WARFARIN;

ATHEROSCLEROSIS; BIOAVAILABILITY; CHOLESTEROL SYNTHESIS; DOG; HYPERCHOLESTEROLEMIA; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RABBIT; REVIEW;

EID: 0032435677     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)